Mitochondrial, nootropic and neuroactive peptides for energy, focus and mood.
Energy, Cognition & Mood covers the mitochondrial, nootropic and neuroactive peptides — compounds aimed at fatigue, focus, memory, neuroprotection, anxiety, mood and sleep. Much of this category rests on Russian clinical research or preclinical work with limited Western replication, so evidence-quality caveats are central to every monograph here.
An evidence-ranked look at the peptides marketed for sleep — DSIP, MK-677, epitalon, CJC-1295 and ipamorelin. The honest headline: no peptide is a proven insomnia treatment, and the best human data are tiny and decades old.
An evidence-graded look at the three peptides marketed for PTSD and trauma — oxytocin, Selank and Semax — separating the mixed human oxytocin RCTs from anxiety-only and preclinical claims.
Energy, Cognition & MoodA clinical, evidence-graded ranking of the peptides marketed for neuroprotection — Cerebrolysin, Semax, ARA-290, SS-31/elamipretide and P021 — separating a modest, mixed human signal from elegant but preclinical-only mechanism.
Energy, Cognition & MoodA clinical, evidence-first ranking of the peptides marketed for mitochondrial dysfunction — elamipretide (SS-31), MOTS-c, humanin and the SHLP family. Only one has any human bioenergetic data, and even that was acute and reversible.
Energy, Cognition & MoodA clinical, evidence-graded ranking of the peptides marketed for memory — Cerebrolysin, Semax, Noopept, Dihexa and P021 — separating the disputed human RCT signal from preclinical mechanism, a retracted-data scandal, and pure marketing.
Energy, Cognition & MoodA clinical, evidence-first review of the peptides marketed for long COVID (PASC) fatigue — thymosin alpha-1, elamipretide (SS-31), aviptadil and BPC-157. The blunt headline: no peptide has a positive long-COVID trial.
Energy, Cognition & MoodA clinical, evidence-graded look at the peptides marketed for focus and "brain fog" — Semax, Selank, Cerebrolysin and the N-Acetyl modified analogs — separating the small human attention signal from preclinical mechanism and pure marketing.
Energy, Cognition & MoodA clinical, evidence-first review of the peptides marketed for fatigue and low energy — elamipretide (SS-31), thymosin alpha-1, MOTS-c, CJC-1295 and ipamorelin. The blunt headline: no peptide has a positive fatigue RCT in healthy people.
Energy, Cognition & MoodA clinical, evidence-first look at the peptides marketed for ME/CFS — thymosin alpha-1, elamipretide (SS-31), MOTS-c and cerebrolysin. The honest headline: no peptide has a completed CFS efficacy trial.
Energy, Cognition & MoodA clinical, evidence-graded look at the three peptides marketed for depression — Cerebrolysin, Selank and Semax — separating secondary-endpoint human data and preclinical antidepressant signals from marketing hype.
Energy, Cognition & MoodA clinical, evidence-graded look at the four peptides marketed for anxiety and stress — Selank, N-Acetyl Selank Amidate, Semax and DSIP — separating the single human anxiety trial from preclinical and marketing claims.
Energy, Cognition & MoodA clinical-editorial breakdown of the peptides marketed for 'adrenal fatigue,' stress and burnout — starting from the fact that 'adrenal fatigue' is not a recognized diagnosis, then grading Selank, DSIP and thymosin alpha-1 honestly against human, animal and absent evidence.
The evidence is mixed and often hard to verify. Peptides such as Semax and Selank have human trials supporting cognitive, anxiolytic and neuroprotective effects, but most of that research is Russian, single-source, and not widely replicated in Western randomized trials. Others, like Dihexa or P21, are preclinical only. We grade each compound to its real evidence level and flag replication and source-quality concerns prominently rather than presenting the strongest claims at face value.
Most cognition and mood peptides are not FDA-approved and are sold in the US as research chemicals. Several — including Semax, DSIP (emideltide) and Epitalon — are among the peptides under FDA compounding review, with advisory-committee hearings scheduled for July 2026. Legal status is unsettled and changing; we date-stamp every regulatory statement and cite primary FDA and trial-registry sources.
Some have limited human signal. DSIP (delta sleep-inducing peptide) has older, small and mixed human sleep studies; Selank has Russian anxiety-disorder trials. The data are thin, dated, or single-source, so we grade conservatively and never present these as proven treatments. As with everything on the site, this is informational content, not medical advice — sleep and anxiety problems warrant a licensed clinician, not a research-chemical peptide.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.
